Radical Cystectomy Improves Survival compared to Trimodal Therapy in Bladder Cancer
A comprehensive meta-analysis compared the treatment modalities for muscle-invasive bladder cancer (MIBC) by using either radical cystectomy (RC) or trimodal therapy (TMT). The findings were published in the Frontiers in Surgery.
This meticulous study explored the academic databases such as Scopus, PubMed, Cochrane, EMBASE, and others from 1966 to December 2023. This yielded data from 14 studies by encompassing 54,816 bladder cancer patients. Out of these, a total of 6,228 underwent trimodal therapy, while 48,588 opted for radical cystectomy.
The results unveiled a significant difference in survival rates with the RC group exhibiting higher overall survival than the TMT group (pooled hazard ratio [HR] = 1.23, 95% CI: 1.18–1.28, P < 0.001). Cancer-specific survival was significantly prolonged in the RC group (pooled HR = 1.47, 95% CI: 1.29–1.67, P < 0.001). Also, the patients in the TMT group faced an increased risk of all-cause mortality compared to their RC counterparts (pooled HR: 1.30, P < 0.001).
The meta-analysis suggests a clear advantage of radical cystectomy in terms of overall survival for the patients of muscle-invasive bladder cancer. The data strongly indicate that cancer-specific survival is also significantly prolonged in addition to better overall survival rates in individuals who opt for radical cystectomy when compared to trimodal therapy.
Also, the outcomes of this study conclude that the patients undergoing trimodal therapy face a higher risk of all-cause mortality by emphasizing the potential superiority of radical cystectomy as a treatment option for muscle-invasive bladder cancer. These findings contribute valuable insights to the ongoing discourse on optimizing therapeutic approaches for this challenging form of cancer.
Source:
Al-Qudimat, A. R., Singh, K., Ojha, L. K., Moustafa, D. A., Elaarag, M., Al-Zoubi, R. M., & Aboumarzouk, O. M. (2023). Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis. In Frontiers in Surgery (Vol. 10). Frontiers Media SA. https://doi.org/10.3389/fsurg.2023.1276746
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.